Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]
Zeidan A, DiNardo C. Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]. Blood And Lymphatic Cancer Targets And Therapy 2025, 15: 69-75. PMID: 40630560, PMCID: PMC12235440, DOI: 10.2147/blctt.s549780.Peer-Reviewed Original ResearchAcute myeloid leukemiaTargeted therapyIDH1 inhibitorsProlonged duration of remissionRefractory acute myeloid leukemiaIDH1-mutated acute myeloid leukemiaProlonged durationOral targeted agentsDuration of remissionAcute myeloid leukemia treatmentQT interval prolongationIndividualized therapy selectionClinical trial studyCombination regimensIntensive chemotherapyAML treatmentInterval prolongationUnfit patientsMyeloid leukemiaClinical benefitTherapeutic optionsSafety profileTherapy selectionDifferentiation syndromeToxicity managementAdvancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]
Zeidan A, Wang E. Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]. Blood And Lymphatic Cancer Targets And Therapy 2025, 15: 77-83. PMID: 40630561, PMCID: PMC12235439, DOI: 10.2147/blctt.s548242.Peer-Reviewed Original ResearchAcute myeloid leukemiaR/R acute myeloid leukemiaAcute myeloid leukemia casesComprehensive molecular testingAcute myeloid leukemia treatmentComprehensive mutational profilingTherapeutic decision-makingOncometabolite 2-hydroxyglutarateAberrant metabolic pathwaysTargeted treatment strategiesClinical practice guidelinesApoptosis of leukemia cellsNCCN guidelinesIDH1-mutantMyeloid leukemiaHeterogeneous malignancyGuideline updateMutation profilesTreatment strategiesMolecular testingTargeted treatmentGenetic mutationsIDH1 inhibitorsLeukemia cellsPractice guidelines
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply